Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Concerta Approved for ADHD, Depression Deleted as Indication for Ritalin
November 12, 2007
- Eisai: Record-High Sales, Profits Driven by Aricept
November 12, 2007
- JMA Calls For Reimbursement of Generics Used Off-label
November 12, 2007
- Debiopharm Licenses DACH-platin MediCelle from NanoCarrier
November 12, 2007
- Sawai Revises Business Forecasts Downward
November 12, 2007
- Taisho Concludes LOI with Pfizer on TS-032
November 12, 2007
- Different Views Presented on NHI Price Listing for Generics 4 Times a Year
November 12, 2007
- About 80% of Intestinal Flora Species Remain Unknown
November 12, 2007
- Korosho to Promote Elimination of Films from Imaging Diagnosis
November 12, 2007
- 11 Generics Receive NHI Price Listing in the 1st Biannual Listing
November 12, 2007
- Pfizer Japan Begins Restructuring to Spur Simultaneous Global Development
November 12, 2007
- MEDICAL DEVICE NEWS IN BRIEF
November 12, 2007
- BUSINESS NEWS IN BRIEF
November 12, 2007
- STPO PRESS／Prasugrel Significantly Reduces Risk of Serious CV Events Compared to Clopidogrel
November 12, 2007
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
November 12, 2007
- TOPICS 2 articles
November 12, 2007
- Chugai to Place Top Priority on Proper Use of Tarceva
November 5, 2007
- Telavancin Received FDA Approvable Letter: Astellas
November 5, 2007
- Chugai's Operating Profits Up 24% in First 3 Qtr
November 5, 2007
- Nexavar, Zevalin, Gracevit, Prezista Recommended for Approval
November 5, 2007
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…